HbA1c and coronary heart disease risk among diabetic patients

Diabetes Care

Volumn 37, Issue 2, 2014, Pages 428-435

  Zhao, Wenhui ^a   Katzmarzyk, Peter T ^a   Horswell, Ronald ^a   Wang, Yujie ^a   Johnson, Jolene ^b   Hu, Gang ^a  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; AFRICAN AMERICAN; AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR RISK; CAUCASIAN; DIABETIC PATIENT; DISEASE ASSOCIATION; ETHNICITY; FEMALE; FOLLOW UP; HUMAN; ISCHEMIC HEART DISEASE; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; RACE DIFFERENCE; SEX DIFFERENCE; SMOKING; BLOOD; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; METABOLISM; MIDDLE AGED; RISK FACTOR;

AFRICAN AMERICANS; AGED; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84893037552     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-1525     Document Type: Article

References (33)

1. Cowie CC, Rust KF, Ford ES, et al. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006. Diabetes Care 2009;32:287-294
2. Moss SE, Klein R, Klein BE. Cause-specific mortality in a population-based study of diabetes. Am J Public Health 1991;81:1158- 1162
3. Balkau B, Hu G, Qiao Q, Tuomilehto J, Borch-Johnsen K, Pyörälä DECODE Study Group; European Diabetes Epidemiology Group. Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor. The DECODE Study. Diabetologia 2004;47: 2118-2128
4. Selvin E, Coresh J, Golden SH, Brancati FL, Folsom AR, Steffes MW. Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study. Arch Intern Med 2005;165:1910-1916
5. Donnan PT, Donnelly L, New JP, Morris AD. Derivation and validation of a prediction score for major coronary heart disease events in a U.K. type 2 diabetic population. Diabetes Care 2006;29:1231-1236
6. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853
7. Gerstein HC, Miller ME, Byington RP, et al.; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559
8. Patel A, MacMahon S, Chalmers J, et al.; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560- 2572
9. Reaven PD, Moritz TE, Schwenke DC, et al.; Veterans Affairs Diabetes Trial. Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis. Diabetes 2009;58:2642-2648
10. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589
11. Skyler JS, Bergenstal R, Bonow RO, et al.; American Diabetes Association; American College of Cardiology Foundation; American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation 2009;119: 351-357
12. Li W, Wang Y, Chen L, et al. Increasing prevalence of diabetes in middle or low income residents in Louisiana from 2000 to 2009. Diabetes Res Clin Pract 2011;94:262- 268
13. Wang Y, Chen L, Horswell R, et al. Racial differences in the association between gestational diabetes mellitus and risk of type 2 diabetes. J Womens Health (Larchmt) 2012;21:628-633
14. Wang Y, Chen L, Xiao K, et al. Increasing incidence of gestational diabetes mellitus in Louisiana, 1997-2009. J Womens Health (Larchmt) 2012;21:319-325
15. Zhang Y, Li W, Wang Y, et al. Increasing prevalence of hypertension in low income residents within Louisiana State University Health Care Services Division Hospital System. Eur J Intern Med 2012;23:e179-e184
16. Hu G, Horswell R, Wang Y, et al. Body mass index and the risk of dementia among Louisiana low income diabetic patients. PLoS ONE 2012;7:e44537
17. Wang Y, Katzmarzyk PT, Horswell R, et al. Racial disparities in diabetic complications in an underinsured population. J Clin Endocrinol Metab 2012; 97:4446-4453
18. Zhao W, Katzmarzyk PT, Horswell R, et al. Aggressive blood pressure control increases coronary heart disease risk among diabetic patients. Diabetes Care 2013;36:3287-3296
19. Zhao W, Katzmarzyk PT, Horswell R, et al. Blood pressure and stroke risk among diabetic patients. J Clin Endocrinol Metab 2013;98:3653-3662
20. American Diabetes Association. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-1197
21. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412
22. Zhang Y, Hu G, Yuan Z, Chen L. Glycosylated hemoglobin in relationship to cardiovascular outcomes and death in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS ONE 2012; 7:e42551
23. Tsugawa Y,Mukamal KJ, Davis RB, TaylorWC, Wee CC. Should the hemoglobin A(1c) diagnostic cutoff differ between blacks and whites?: a cross-sectional study. Ann Intern Med 2012;157:153-159
24. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002;287:2570-2581
25. Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 2002;288:2579-2588
26. Mazzone T, Chait A, Plutzky J. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet 2008;371: 1800-1809
27. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-393
28. Kanaya AM, Adler N, Moffet HH, et al. Heterogeneity of diabetes outcomes among Asians and Pacific Islanders in the US: the diabetes study of northern california (DISTANCE). Diabetes Care 2011; 34:930-937
29. Karter AJ, Ferrara A, Liu JY, Moffet HH, Ackerson LM, Selby JV. Ethnic disparities in diabetic complications in an insured population. JAMA 2002;287:2519-2527
30. Wilson PW,D'Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005;112:3066-3072
31. Ho KK, Anderson KM, KannelWB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993;88: 107-115
32. Hu G, Tuomilehto J, Silventoinen K, Barengo N, Jousilahti P. Joint effects of physical activity, body mass index, waist circumference and waist-to-hip ratio with the risk of cardiovascular disease among middle-aged Finnish men and women. Eur Heart J 2004;25:2212-2219
33. Pajunen P, Koukkunen H, Ketonen M, et al. The validity of the Finnish Hospital Discharge Register and Causes of Death Register data on coronary heart disease. Eur J Cardiovasc Prev Rehabil 2005;12:132-137